SCHEMBL1032844

SCHEMBL1032844

CCCN(CCC)CCOc1ccc(NS(=O)(=O)c2ccc(C(C)C)cc2)cn1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
PABPC1 P11940 1/20 0.42
LMNA P02545 3/20 0.41
SMN1; SMN2 Q16637 3/20 0.41
ALDH1A1 P00352 2/20 0.41
MAPT P10636 1/20 0.41
PKM P14618 1/20 0.41
HTT P42858 2/20 0.41
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2D6 P10635 1/20 0.41
CYP2C9 P11712 1/20 0.41
TSHR P16473 1/20 0.41
CYP2C19 P33261 1/20 0.41
POLB P06746 1/20 0.40
TRIM24 O15164 1/20 0.39
BRD1 O95696 1/20 0.39
BRPF1 P55201 1/20 0.39
NPC1 O15118 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL4248062 0.99 MEN1 (0.41) MEN1KMT2APABPC1LMNASMN1; SMN2
SCHEMBL1032033 0.88 CACNA1B (0.46) MEN1KMT2APABPC1LMNASMN1; SMN2
Hydrochloric Acid SCHEMBL4247175 0.87 CACNA1B (0.45) MEN1KMT2APABPC1LMNASMN1; SMN2
SCHEMBL1032588 0.84 MEN1 (0.43) MEN1KMT2APABPC1LMNASMN1; SMN2
Hydrochloric Acid SCHEMBL4244246 0.83 ADRB2 (0.42) MEN1KMT2APABPC1LMNASMN1; SMN2
SCHEMBL2466084 0.76 FFAR1 (0.51) MEN1KMT2ALMNASMN1; SMN2ALDH1A1
Hydrochloric Acid SCHEMBL4914708 0.75 FFAR1 (0.50) MEN1KMT2ALMNASMN1; SMN2ALDH1A1
SCHEMBL2468223 0.73 LMNA (0.46) LMNASMN1; SMN2ALDH1A1MAPTPKM
SCHEMBL2468236 0.70 ADRB2 (0.48) LMNASMN1; SMN2ALDH1A1MAPTPKM
Hydrochloric Acid SCHEMBL4925564 0.70 ADRB2 (0.47) LMNASMN1; SMN2ALDH1A1MAPTPKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2013179-B1 ARYLOXYETHYLAMINE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR ABBOTT GMBH & CO KG (DE) 2011-01-19 EP disclosed
EP-2013179-A1 ARYLOXYETHYLAMINE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR Abbott GmbH & Co. KG (DE) 2009-01-14 EP disclosed
WO-2007118859-A1 ARYLOXYETHYLAMINE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR ABBOTT GMBH & CO. KG (DE) 2007-10-25 WO disclosed